|
 |
|
|||||||
|
|||||||||
Diabetes 54:838-845, 2005
© 2005 by the American Diabetes Association, Inc.
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Prevents Renal Insufficiency and Mesangial Matrix Expansion in Diabetic db/db Mice
1 Department of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan
2 Marutamachi Otowa Hospital, Kyoto, Japan
3 Daiichi Suntory Biomedical Research, Mishima, Osaka, Japan
4 Second Department of Medicine, Asahikawa Medical College, Asahikawa, Hokkaido, Japan
We have previously reported that N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), which is a tetrapeptide hydrolyzed by ACE, inhibits the transforming growth factor-ß (TGF-ß)-induced expression of extracellular matrix proteins via inhibition of the Smad signaling in human mesangial cells. To test in vivo the antifibrotic efficacy of Ac-SDKP, we examined whether long-term Ac-SDKP treatment can prevent renal insufficiency and glomerulosclerosis in diabetic db/db mice. Diabetic db/db mice or nondiabetic db/m mice were treated with Ac-SDKP for 8 weeks using osmotic minipumps. The treatment with Ac-SDKP increased plasma Ac-SDKP concentrations by approximately threefold in both groups but did not affect the blood glucose levels. Histologically, the increased glomerular surface area, mesangial matrix expansion, and overproduction of extracellular matrix proteins in db/db mice were significantly inhibited by Ac-SDKP. Furthermore, Ac-SDKP treatment normalized the increased plasma creatinine value in db/db mice, whereas the albuminuria in Ac-SDKP–treated db/db mice was somewhat decreased as compared with nontreated db/db mice, although the difference was not statistically significant. In addition, the nuclear translocation of Smad3 was inhibited by Ac-SDKP. These results demonstrate that long-term Ac-SDKP treatment ameliorates renal insufficiency and glomerulosclerosis in db/db mice via inhibition of TGF-ß/Smad pathway, suggesting that Ac-SDKP could be useful in the treatment of diabetic nephropathy.
Address correspondence and reprint requests to Daisuke Koya, MD, Department of Medicine, Shiga University of Medical Science, Otsu, Shiga, 520-2192, Japan. E-mail: koya{at}belle.shiga-med.ac.jp
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Cavasin, T.-D. Liao, X.-P. Yang, J. J. Yang, and O. A. Carretero Decreased Endogenous Levels of Ac-SDKP Promote Organ Fibrosis Hypertension, July 1, 2007; 50(1): 130 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Peng, O. A. Carretero, T.-D. Liao, E. L. Peterson, and N.-E. Rhaleb Role of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline in the Antifibrotic and Anti-Inflammatory Effects of the Angiotensin-Converting Enzyme Inhibitor Captopril in Hypertension Hypertension, March 1, 2007; 49(3): 695 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lee, W. Kim, S.-O. Moon, M. J. Sung, D. H. Kim, K. P. Kang, K. Y. Jang, S. Y. Lee, B. H. Park, G. Y. Koh, et al. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes Nephrol. Dial. Transplant., February 1, 2007; 22(2): 396 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Omata, H. Taniguchi, D. Koya, K. Kanasaki, R. Sho, Y. Kato, R. Kojima, M. Haneda, and N. Inomata N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Ameliorates the Progression of Renal Dysfunction and Fibrosis in WKY Rats with Established Anti-Glomerular Basement Membrane Nephritis J. Am. Soc. Nephrol., March 1, 2006; 17(3): 674 - 685. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |